Third quarter and nine months ended September 30, 2026
Filed Nov 4, 2026Summit reported third-quarter GAAP net loss of $208.4 million and ended the quarter with $629.8 million in cash and investments, before receiving AstraZeneca's $2.0 billion strategic equity investment after quarter-end.
The company reduced its GAAP net loss from the prior-year quarter and secured a $2.0 billion post-quarter-end equity investment, but non-GAAP operating expenses and non-GAAP net loss increased as ivonescimab clinical development expanded, while the pending BLA faces a November 14, 2026 PDUFA goal action date after the company disclosed that the primary OS analysis did not achieve statistical significance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Third quarter 2026 GAAP research and development expensesGAAP | $169.1M | – | – |
| Third quarter 2026 non-GAAP research and development expensesnon-GAAP | $145.2M | – | – |
| Third quarter 2026 GAAP general and administrative expensesGAAP | $45.5M | – | – |
| Third quarter 2026 non-GAAP general and administrative expensesnon-GAAP | $21.7M | – | – |
| Third quarter 2026 GAAP operating expensesGAAP | $214.6M | – | – |
| Third quarter 2026 non-GAAP operating expensesnon-GAAP | $166.9M | – | – |
| Third quarter 2026 other income, netGAAP | $6.2M | – | – |
| Third quarter 2026 GAAP net lossGAAP | $208.4M | – | – |
| Third quarter 2026 non-GAAP net lossnon-GAAP | $160.7M | – | – |
| Third quarter 2026 GAAP net loss per basic and diluted common shareGAAP | $(0.26) | – | – |
| Third quarter 2026 non-GAAP net loss per basic and diluted common sharenon-GAAP | $(0.20) | – | – |
| Third quarter 2026 basic and diluted common sharesGAAP | 798.2M | – | – |
| Third quarter 2026 stock-based compensation in research and developmentother | −$23.9M | – | – |
| Third quarter 2026 stock-based compensation in general and administrative expensesother | −$23.8M | – | – |
| Third quarter 2026 stock-based compensation in operating expensesother | −$47.7M | – | – |
| Third quarter 2026 stock-based compensation adjustment to net loss per basic and diluted common shareother | $0.06 | – | – |
| Nine months ended September 30, 2026 GAAP research and development expensesGAAP | $459.5M | – | – |
| Nine months ended September 30, 2026 non-GAAP research and development expensesnon-GAAP | $387.1M | – | – |
| Nine months ended September 30, 2026 GAAP general and administrative expensesGAAP | $170.8M | – | – |
| Nine months ended September 30, 2026 non-GAAP general and administrative expensesnon-GAAP | $54M | – | – |
| Nine months ended September 30, 2026 GAAP operating expensesGAAP | $630.3M | – | – |
| Nine months ended September 30, 2026 non-GAAP operating expensesnon-GAAP | $441.1M | – | – |
| Nine months ended September 30, 2026 other income, netGAAP | $16.8M | – | – |
| Nine months ended September 30, 2026 GAAP net lossGAAP | $613.5M | – | – |
| Nine months ended September 30, 2026 non-GAAP net lossnon-GAAP | $424.3M | – | – |
| Nine months ended September 30, 2026 GAAP net loss per basic and diluted common shareGAAP | $(0.78) | – | – |
| Nine months ended September 30, 2026 non-GAAP net loss per basic and diluted common sharenon-GAAP | $(0.54) | – | – |
| Nine months ended September 30, 2026 basic and diluted common sharesGAAP | 784M | – | – |
| Nine months ended September 30, 2026 stock-based compensation in research and developmentother | −$72.4M | – | – |
| Nine months ended September 30, 2026 stock-based compensation in general and administrative expensesother | −$116.8M | – | – |
| Nine months ended September 30, 2026 stock-based compensation in operating expensesother | −$189.2M | – | – |
| Nine months ended September 30, 2026 stock-based compensation adjustment to net loss per basic and diluted common shareother | $0.24 | – | – |
| Cash and cash equivalents and short-term investments at September 30, 2026GAAP | $629.8M | – | – |
| Total assets at September 30, 2026GAAP | $692.9M | – | – |
| Total liabilities at September 30, 2026GAAP | $128.2M | – | – |
| Total stockholders' equity at September 30, 2026GAAP | $564.7M | – | – |
| Nine months ended September 30, 2026 net cash used in operating activitiesGAAP | −$423.2M | – | – |
| Nine months ended September 30, 2026 net cash provided by investing activitiesGAAP | $18.5M | – | – |
| Nine months ended September 30, 2026 net cash provided by financing activitiesGAAP | $330.3M | – | – |
| Nine months ended September 30, 2026 effect of exchange rate changes on cashGAAP | — | – | – |
| Nine months ended September 30, 2026 decrease in cash, cash equivalents and restricted cashGAAP | −$74.4M | – | – |
Capital returns
- During the third quarter of 2026, the company raised $94.1 million in gross proceeds through its ATM facility.
- On October 5, 2026, AstraZeneca completed a $2.0 billion strategic equity investment in Summit.
- AstraZeneca purchased an aggregate of approximately 108,955 shares of preferred stock convertible into shares of common stock of Summit at a 1:1,000 ratio.
- At the conversion ratio, the investment represents a common stock price equal to $18.36.
What drove it
- Third-quarter GAAP operating expenses declined because of a decrease in stock-based compensation expense of $83.1 million primarily related to the modification to performance-based stock option awards during the second quarter of 2025.
- Third-quarter non-GAAP operating expenses increased primarily because of expansion of clinical studies and development costs related to ivonescimab.
- Third-quarter GAAP R&D expenses increased with the expansion of clinical studies and development costs related to ivonescimab, partly offset by a decrease in stock-based compensation expense of $16.7 million.
- Third-quarter non-GAAP G&A expenses increased with expansion of infrastructure and headcount to support ivonescimab development.
- Enrollment in both squamous and non-squamous NSCLC cohorts of HARMONi-3 is complete.
- HARMONi-GI3 enrollment is expected to include 900 patients and is currently expected to complete in Q3 2027.
Concerns
- The FDA stated that a statistically significant OS benefit is necessary to support marketing authorization in the HARMONi setting, while the primary OS analysis showed a positive trend without achieving a statistically significant result.
- Nine-month non-GAAP operating expenses were $441.1 million, compared to $248.9 million in the prior-year period.
- Nine-month net cash used in operating activities was $(423.2) million, compared to $(221.0) million in the prior-year period.
- Cash and cash equivalents and short-term investments declined to $629.8 million at September 30, 2026 from $713.4 million at December 31, 2025, before the AstraZeneca investment closed.
- Ivonescimab is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe.
What to watch
- The FDA's November 14, 2026 PDUFA goal action date for the pending HARMONi BLA.
- The HARMONi-3 squamous cohort primary PFS analysis and planned early interim OS analysis, expected in the fourth quarter of 2026.
- The HARMONi-3 non-squamous cohort PFS analysis, expected in the first half of 2027.
- HARMONi-7 enrollment completion, expected in 2027.
- HARMONi-GI3 enrollment completion, currently expected in Q3 2027.
- Initial data from the Arcus casdatifan collaboration study, expected to be generated by mid-2027.
Balance sheet and cash flow
- Aggregate cash and cash equivalents and short-term investments were $629.8 million at September 30, 2026, compared to $713.4 million at December 31, 2025.
- Total assets were $692.9 million at September 30, 2026, compared to $751.2 million at December 31, 2025.
- Total liabilities were $128.2 million at September 30, 2026, compared to $92.3 million at December 31, 2025.
- Nine-month net cash used in operating activities was $(423.2) million, compared to $(221.0) million for the prior-year period.
- Nine-month net cash provided by financing activities was $330.3 million, compared to $43.7 million for the prior-year period.
Analysis
Summit remains a clinical-stage oncology company in this release, with no revenue reported. Third-quarter GAAP operating expenses were $214.6 million, below $234.2 million in the prior-year quarter, and GAAP net loss was $208.4 million, compared with $231.8 million. The reported GAAP improvement was driven by lower stock-based compensation. On a non-GAAP basis, operating expenses rose to $166.9 million from $103.4 million and net loss rose to $160.7 million from $101.0 million, reflecting the growing cost of ivonescimab clinical studies and development.
R&D was the principal area of spending. Third-quarter GAAP R&D expenses were $169.1 million versus $131.1 million, while non-GAAP R&D expenses were $145.2 million versus $90.5 million. Nine-month GAAP R&D expenses were $459.5 million and non-GAAP R&D expenses were $387.1 million. The company also expanded infrastructure and headcount, with third-quarter non-GAAP G&A expenses of $21.7 million compared with $12.9 million. These figures align with a development program that includes NSCLC, CRC, UC and RCC trials, alongside additional collaborations in gastrointestinal, breast, lung, head and neck, and biliary tract cancer settings.
Liquidity was strengthened materially after the reporting period. Summit ended September 30 with $629.8 million in cash and cash equivalents and short-term investments, down from $713.4 million at December 31, 2025. Nine-month operating cash use was $(423.2) million. The company raised $94.1 million in gross ATM proceeds during the quarter, and AstraZeneca completed a $2.0 billion strategic equity investment on October 5, 2026. The post-quarter investment is intended to support continued acceleration of ivonescimab development.
The near-term clinical and regulatory focus is the HARMONi BLA, for which the FDA set a November 14, 2026 PDUFA goal action date. HARMONi met its PFS primary endpoint, but the primary OS analysis showed a positive trend without achieving statistical significance, and the company stated that the FDA noted a statistically significant OS benefit is necessary for marketing authorization in this setting. Updated June 2026 global ITT results reported an OS hazard ratio of 0.76, with a 95% CI of 0.61 – 0.95 and nominal p=0.0151. The next operating catalysts cited are HARMONi-3 squamous-cohort PFS and early OS analyses expected in the fourth quarter of 2026, followed by the non-squamous PFS analysis in the first half of 2027.
Clinical breadth continued to expand during and after the quarter. HARMONi-GU1 site activation and enrollment began, SMT112-216 began enrollment with plans to enroll approximately 100 patients, and Summit entered additional collaborations involving AstraZeneca, Daiichi Sankyo and others. The company also stated that it has agreed to support more than 65 investigator-sponsored trials, of which 26 have started and are actively enrolling. This expansion increases the number of potential development opportunities, while the reported non-GAAP expense and operating cash-use figures show the associated funding requirements.
Management, verbatim
This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others.
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit
Our global clinical development program for ivonescimab continues to broaden, with the announcement of ivonescimab combination collaborations with Datroway® and sone-ve, alongside new studies in bladder cancer with HARMONi-GU1, in biliary tract cancer with EA2251, and in kidney cancer with SMT112-216 and Arcus’ ARC-20 platform study.
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit
Not in the filing
stated, not guessed- Total revenue was not reported.
- Segment revenue and segment operating metrics were not reported.
- Gross profit and gross margin were not reported.
- Operating income or loss was not reported as a separate line item.
- Income tax expense, benefit, or tax rate was not reported.
- Debt was not reported.
- Free cash flow was not reported.
- Share repurchases and dividends were not reported.
- Financial guidance was not reported.
- Previous-release outlook was not provided. შესაბამისად, no comparison with prior guidance is available.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.